ABK Biomedical Inc.
Improving treatment options for patients with hypervascular tumors
ABK Raises $30M USD in Series B Financing
ABK Biomedical partners with the Canadian Nuclear Isotope Council
New strategic partnership with the University of Missouri Research Reactor Center
ABK appoints Michael J Mangano as President and CEO
A breakthrough combination of Y-90 for radioembolization and a radiopaque glass composition allowing unprecedented procedural visualization.
Radiopaque bland embolization product allowing direct visualiztion at the target site.
President and CEO
Chief Financial Officer
Chief Commercial Officer
Co-Founder and Chief Medical Officer
Vice President, Manufacturing and Facilities
VP Clinical Development and Regulatory Affairs
VP R&D and Nuclear Operations
ABK Biomedical Inc. provides and continues to provide accurate information on its website. However, ABK Biomedical Inc. assumes no responsibility for accuracy and/or completeness, express or implied, as to the information contained or omitted and/or the products described. Furthermore, ABK Biomedical may change the products mentioned at any time without notice. ABK Biomedical Inc. is a Pre-clinical stage company engaged in the active research and development of new medical devices. ABK Biomedical products are considered investigational only and are not FDA cleared for use..
(C) Copyright 2019 – All International Rights Reserved – ABK Biomedical Inc.